meiver
  • How it works
  • Features
  • Pricing
  • Blog
Sign inGet started free →
How it worksFeaturesPricingBlogSign in
BMR in Pharma: Common Audit Findings and How to Avoid Them
Home›Blog›BMR in Pharma: Common Audit Findings and How to Avoid Them

BMR in Pharma: Common Audit Findings and How to Avoid Them

Published:06 November 2026

A BMR in pharma is more than a production form. It is the evidence trail for a specific batch: what was manufactured, which materials and equipment were used, who performed each activity, what happened during processing, and whether the batch followed the approved instructions.

India’s revised Schedule M was notified through G.S.R. 922(E) on 28 December 2023. CDSCO subsequently allowed eligible manufacturers with turnover up to ₹250 crore to seek additional implementation time, but not beyond 31 December 2025. As of 2026, manufacturers should therefore assess their documentation against the revised framework rather than rely on the older implementation timeline. CDSCO

What Is a BMR in the Pharma Industry?

The batch manufacturing record in pharmaceutical industry documentation shows what actually happened during one manufacturing batch.

It helps to separate two concepts:

  • Master Formula / Master Batch Record: approved instructions describing how the product is intended to be manufactured.

  • BMR / executed batch record: completed evidence showing how a particular batch was actually manufactured.

Terms such as BPR BMR in pharma or BPCR may also be used by different organisations, but terminology is not completely uniform.

CDSCO requirements for Master Formula Records include raw-material quantities, equipment, manufacturing and control instructions, critical parameters, theoretical yields and in-process testing. CDSCO

Common BMR-Related Audit Findings

Most BMR problems are not caused by the absence of a form. They arise when the record cannot reliably reconstruct what happened.

Common audit-risk patterns include:

  • missing, incomplete or delayed entries;

  • unexplained corrections or overwriting;

  • missing operator or reviewer signatures;

  • undocumented deviations;

  • material quantity or yield discrepancies;

  • incomplete reconciliation;

  • missing in-process results;

  • uncontrolled attachments; and

  • failure to follow the approved Master Formula or SOP.

The practical rule is simple: record the activity when it happens, identify who performed it, and document exceptions rather than trying to reconstruct them later.

BMR Audit-Readiness Process

Manufacturing stage

What the BMR should capture

Audit-risk control

Batch setup

Product, batch number, approved formula/reference

Prevent wrong-document use

Material issue

Material lots, quantities, dispensing details

Maintain traceability and reconciliation

Processing

Equipment, operators, timings, critical parameters

Prove contemporaneous execution

In-process/QC

IPC results, deviations, yields, reviewer checks

Support quality and release decisions

Review/release

Reconciliation, deviations, approvals, final status

Confirm controlled batch closure

Electronic Batch Records: Better Control, New Responsibilities

An electronic batch record in pharma can reduce handwriting issues, missing fields and document retrieval delays—but digitisation alone does not create compliance.

Computerised GMP systems require appropriate validation, controlled access, backups and audit trails. WHO guidance expects relevant audit trails to preserve changes, identify users and timestamps, and allow activities to be reconstructed. World Health Organization

So when assessing electronic batch record software for pharma, manufacturers should evaluate governance and data integrity, not simply whether the system replaces paper.

From BMR Completion to Batch Record Release

Batch record release should happen only after the required manufacturing, reconciliation, deviation and quality evidence has been reviewed.

The BMR and Certificate of Analysis serve different purposes. The BMR documents execution of manufacturing; the CoA reports specified analytical results. CDSCO rules also require testing records for raw materials and finished-product batches. CDSCO

For brands managing multiple batches, evidence can become fragmented across paper files, spreadsheets and shared folders. Meiver is designed around batch-level traceability, linking batches with production stages, supporting documents and quality evidence rather than acting as an ERP or eBMR execution system. MeiverFeatureReference

Conclusion

A strong pharma batch manufacturing record should answer five questions without guesswork: what happened, who did it, when it happened, whether the approved process was followed, and how exceptions were handled.

Good BMR discipline therefore protects more than audit readiness. It strengthens traceability, investigation quality, recall readiness and confidence in every released batch.

FAQs

1. What is the difference between a master batch record vs executed batch record?

The master record contains approved manufacturing instructions. The executed record documents what actually occurred for a specific batch.

2. Is an electronic BMR mandatory in India?

Not generally. Electronic systems can improve control, but manufacturers must manage validation, access, audit trails, security, backups and data integrity appropriately.

3. What are GMP Certificate of Analysis requirements in relation to BMR?

For GMP certificate of analysis requirements, think of the CoA as analytical evidence supporting quality decisions. It complements—but does not replace—the manufacturing record.

4. Can traceability software replace the BMR?

No. Traceability systems can connect batch, stage and quality evidence, but they should not automatically be treated as a validated BMR, MES or QMS unless their validated intended use supports that function.

Suggested internal links: Meiver Pharma Solutions, Batch & Stages Management, Certificate of Analysis, Traceability, and Recall Management pages. Meiver’s site structure specifically positions its Pharma solution around batch tracking, CoA proof, regulatory support and verified product trust. Meiver Page Structure

This structure also aligns with Google’s current guidance: useful, original, people-first information remains foundational for both conventional Search and generative AI experiences; Google does not require a separate AEO/GEO optimisation system.


Related Articles
How to Run a Mock Recall in Under an Hour
How to Run a Mock Recall in Under an Hour
18 November 2026
FSSAI Audit Checklist: Readiness Guide for Food Manufacturing Units
FSSAI Audit Checklist: Readiness Guide for Food Manufacturing Units
18 November 2026
Global Batch Traceability in SAP: When ERP Traceability Isn’t Enough for Customer-Facing Proof
Global Batch Traceability in SAP: When ERP Traceability Isn’t Enough for Customer-Facing Proof
17 November 2026
Get in touch

Contact Us

Have questions about Meiver’s traceability platform? Our team is ready to help you get started.

By submitting, you agree to our Privacy Policy. We never share your data.

meiver

Full-chain traceability for food, pharma and nutraceutical brands — from raw material to verified proof.

Product

FeaturesPricingHow it works

Resources

BlogHelp CenterContact

Legal

Privacy PolicyTerms & Conditions

Built for trust

Blockchain-anchored records
Entity-scoped access control
Full audit trail
© 2026 Meiver. All rights reserved.Truth. Verified. Trusted. · meiver.io